Chimerix Inc
(STU:CXF)
€
0.824
0.016 (1.98%)
Market Cap: 76.31 Mil
Enterprise Value: -71.55 Mil
PE Ratio: 0
PB Ratio: 0.46
GF Score: 45/100 - Q1 2024 Chimerix Inc Earnings Call TranscriptMay 01, 2024Earnings
- Q4 2023 Chimerix Inc Earnings Call TranscriptFeb 29, 2024€1.12 (-7.95%)Earnings
- Q3 2023 Chimerix Inc Earnings Call TranscriptNov 02, 2023€0.8992 (+2.51%)Earnings
- Q2 2023 Chimerix Inc Earnings Call TranscriptAug 03, 2023€1.04Earnings
- Chimerix Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Q1 2023 Chimerix Inc Earnings Call TranscriptMay 04, 2023€1.02 (-0.44%)Earnings
- Q4 2022 Chimerix Inc Earnings Call TranscriptMar 02, 2023€1.55 (+6.01%)Earnings
- Chimerix Inc at JPMorgan Healthcare Conference TranscriptJan 12, 2023
- Q3 2022 Chimerix Inc Earnings Call TranscriptNov 03, 2022€1.82 (-4.55%)Earnings
- Q2 2022 Chimerix Inc Earnings Call TranscriptAug 08, 2022€2.26 (-10.79%)Earnings
- Q1 2022 Chimerix Inc Earnings Call TranscriptMay 16, 2022€2.04 (-41.86%)Earnings
- Q4 2021 Chimerix Inc Earnings Call TranscriptMar 01, 2022€4.87 (-1.78%)Earnings
- Chimerix Inc to Discuss Positive ONC201 Data in Recurrent H3 K27M-mutant Diffuse Midline Glioma Call TranscriptNov 22, 2021
- Chimerix Inc at Credit Suisse Healthcare Conference (Virtual) TranscriptNov 08, 2021
- Q3 2021 Chimerix Inc Earnings Call TranscriptNov 04, 2021€5.21 (+4.73%)Earnings
- Q2 2021 Chimerix Inc Earnings Call TranscriptAug 05, 2021€5.57 (+4.90%)Earnings
- Chimerix Inc at Jefferies Healthcare Conference (Virtual) TranscriptJun 01, 2021
- Q1 2021 Chimerix Inc Earnings Call TranscriptMay 06, 2021€6.6 (-11.06%)Earnings
- Q4 2020 Chimerix Inc Earnings Call TranscriptFeb 25, 2021€8.48 (+3.41%)Earnings
- Chimerix Inc to Acquire Oncoceutics Inc - Conference Call TranscriptJan 08, 2021
- Chimerix Inc at Credit Suisse Healthcare Conference (Virtual) TranscriptNov 12, 2020
- Q3 2020 Chimerix Inc Earnings Call TranscriptNov 05, 2020€2.5 (+0.81%)Earnings
- Q2 2020 Chimerix Inc Earnings Call TranscriptAug 10, 2020€2.68Earnings
- Chimerix Inc DSTAT Clinical Update Conference Call TranscriptApr 29, 2020
- Q4 2019 Chimerix Inc Earnings Call TranscriptFeb 25, 2020€1.71 (+11.76%)Earnings
- Chimerix Inc at Credit Suisse Healthcare Conference - Scottsdale TranscriptNov 13, 2019
- Q3 2019 Chimerix Inc Earnings Call and Operational Updates TranscriptNov 05, 2019€1.39 (-2.11%)Earnings
- Chimerix Inc CX-01 Call TranscriptJul 31, 2019
- Q1 2019 Chimerix Inc Earnings Call TranscriptMay 09, 2019€2.5 (+6.38%)Earnings
- Q4 2018 Chimerix Inc Earnings Call TranscriptMar 05, 2019€1.8 (-8.16%)Earnings
Chimerix Inc at Jefferies Healthcare Conference Transcript
Jun 07, 2023 / 07:30PM GMT
Release Date Price:
€1.33
(-3.97%)
Maury Raycroft
Jefferies - Analyst
Hi, everyone. My name is Maury Raycroft, and I'm one of the Biotech Analysts at Jefferies. I'm happy to introduce our guest today, Mike Sherman, President and CEO of Chimerix, and Mike Andriole, the CFO. This is going to be a fireside chat format. Thanks so much for joining us today.
Mike Sherman
Chimerix, Inc. - CEO
Thanks for having us, Maury.
Mike Andriole
Chimerix, Inc. - CFO and Chief Business Officer
Thanks, Maury.
Maury Raycroft
Jefferies - Analyst
And maybe to start off if -- for those who are new to the story, if you want to provide a one minute intro to Chimerix.
Mike Sherman
Chimerix, Inc. - CEO
Sure. Our most advanced program, ONC201 or dordaviprone is being developed in H3 K27M, so a genetically mutated patient population within glioma. The Phase 2 trial, which is the basis for advancing to that gave us a really good insight into definitive durable responses in the relapse
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)